Nitrosamines: EMA aligns recommendations for sartans with those for other medicines

The main change concerns the limits for nitrosamines, which will now apply to the finished products (e.g. tablets). These limits, should ensure that excess risk of cancer from nitrosamines in any sartan medicines is below 1 in 100,000 for a person taking lifelong medication.

European Medicines Agency